Proteomic studies in urological malignancies

Contributions to Nephrology

Volumn 141, Issue , 2004, Pages 257-279

  Ferguson, Roisean E ^a   Selby, Peter J ^a   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3142721641     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (120)

1. National Cancer Institute Surveillance Epidemiology and End Results Program. http://seer cancer gov/2003
2. Liotta LA, Kohn EC, Petricoin EF: Clinical proteomics: Personalized molecular medicine. JAMA 2001;286:2211-2214.
3. Liotta L, Petricoin E: Molecular profiling of human cancer. Nat Rev Genet 2000; 1:48-56.
4. Gasparini G, Gion M: Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints. Cancer J 2000;6:117-131.
5. Milenic DE: Monoclonal antibody-based therapy strategies: Providing options for the cancer patient. Curr Pharm Des 2002;8:1749-1764.
6. Hanash SM, Bobek MP, Rickman DS, Williams T, Rouillard JM, Kuick R, Puravs E: Integrating cancer genomics and proteomics in the post-genome era. Proteomics 2002;2:69-75.
7. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
8. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412: 822-826.
9. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000;60:4161-4166.
10. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, Selby PJ: Proteomics: New perspectives, new biomedical opportunities. Lancet 2000;356:1749-1756.
11. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
12. Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA, Ahn NG: Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 2000;6:1343-1354.
13. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Rev 2001;21:499-512.
14. Chapman K: The ProteinChip Biomarker System from Ciphergen Biosystems: A novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002;30:82-87.
15. Celis A, Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, Hein B, Ostergaard M, Wolf H, Orntoft T, Celis JE: Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 1999;20:355-361.
16. Paweletz CP, Liotta LA, Petricoin EF III: New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001;57:160-163.
17. Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A: Proteinchip® surface-enhanced laser desorption/ionization mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999;2:264-276.
18. Craven RA, Totty N, Harnden P, Selby PJ, Banks RE: Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: Evaluation of tissue preparation and sample limitations. Am J Pathol 2002;160:815-822.
19. Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2000; Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, I ARC Press, 2001.
20. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmoller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, Okkels H, Romkes M, Roots I, Rothman N: Cigarette smoking, N-acetyltransferase-2 acetylation status and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000;9:461-467.
21. Johansson SL, Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13:291-298.
22. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-1221.
23. Knowles MA: What we could do now: Molecular pathology of bladder cancer. Mol Pathol 2001; 54:215-221.
24. Bedwani R, Renganathan E, El Kwhsky F, Braga C, Abu Seif HH, Abul AT, Zaki A, Franceschi S, Boffetta P, La Vecchia C: Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 1998;77:1186-1189.
25. Metts MC, Metts JC, Milito SJ, Thomas CR Jr: Bladder cancer: A review of diagnosis and management. J Natl Med Assoc 2000;92:285-294.
26. Pow-Sang JM, Seigne JD: Contemporary management of superficial bladder cancer. Cancer Control 2000;7:335-339.
27. Pashos CL, Botteman MF, Laskin BL, Redaelli A: Bladder cancer: Epidemiology, diagnosis and management. Cancer Pract 2002; 10:311-322.
28. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I: Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46:595-605.
29. Grossman HB, Dinney CPN: Markers of bladder cancer - State of the art. Urol Oncol 2000;5: 3-10.
30. Orntoft TF, Wolf H: Molecular alterations in bladder cancer. Urol Res 1998;26:223-233.
31. Van der Poel HG: Markers for recurrence of superficial bladder cancer: What is valid? Curr Opin Urol 1999;9:401-406.
32. Kausch I, Bohle A: Molecular aspects of bladder cancer. III. Prognostic markers of bladder cancer. Eur Urol 2002;41:15-29.
33. Mazhar D, Waxman J: Prostate cancer. Postgrad Med J 2002;78:590-595.
34. Dong JT: Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20:173-193.
35. Burton JL, Oakley N, Anderson JB: Recent advances in the histopathology and molecular biology of prostate cancer. BJU Int 2000;85:87-94.
36. Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, Spurr NK, Snary D: Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 1998;78:1296-1300.
37. Teng DH, Hu R, Lin H, Davis T, Hiev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA: MMAC1/PTEN mutations in primary tumor specimens and cell lines. Cancer Res 1997;57:5221-5225.
38. Foster CS: Predictive factors in prostatic hyperplasia and neoplasia. Hum Pathol 1990;21:575-577.
39. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
40. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
41. Brawer MK: Prostate-specific antigen: Current status. CA Cancer J Clin 1999;49:264-281.
42. Bok RA, Small EJ: Blood-borne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002;2:918-926.
43. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. C A Cancer J Clin 2000;50: 7-33.
44. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 1998;352:1691-1696.
45. Pantuck AJ, Zisman A, Belldegrun AS: The changing history of renal cell carcinoma. J Urol 2003;166:1611-1623.
46. Cancer Research. UK Stats 2003.
47. Zbar B, Brauch H, Talmadge C, Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987;327:721-724.
48. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou FW, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng YK, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
49. Pereira T, Zheng X, Ruas JL, Tanimoto K, Poellinger L: Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-la by the von Hippel-Lindau tumor suppressor gene product. J Biol Chem 2003;278:6816-6823.
50. Huang LE, Pete EA, Schau M, Milligan J, Gu J: Leu-574 of HIF-lα is essential for the von Hippel-Lindau-mediated degradation pathway. J Biol Chem 2002;277:41750-4755.
51. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G: Loss of heterozygosity at chromosomes 8p, 9p and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 1997;183:151-155.
52. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A: Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090-1095.
53. Nelson JB, Marshall FF: Renal cell carcinoma: Management and prognosis. Urol Oncol 1997; 12: 174-194.
54. Ljungberg B, Rasmuson T, Grankvist K: Erythropoietin in renal cell carcinoma: Evaluation of its usefulness as a tumor marker. Eur Urol 1992;21:160-163.
55. Gross AJ, Dieckmann KP: Neuron-specific enolase: A serum tumor marker in malignant germcell tumors? Eur Urol 1993;24:277-278.
56. Partin AW, Criley SR, Steiner MS, Hsieh K, Simons JW, Lumadue J, Carter HB, Marshall FF: Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor volume. Urology 1995;45:211-217.
57. 1, is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 1996;8:794-798.
58. Onufrey V Mohiuddin M: Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 1985;11:2007-2009.
59. Figlin RA: Renal cell carcinoma: Management of advanced disease. J Urol 1999;161:381-386.
60. Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer 1997;80:1198-1220.
61. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-417.
62. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489-494.
63. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81: 741-746.
64. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. Curr Opinlmmunol 1997;9:709-716.
65. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999;83:456-464.
66. Celis JE, Ostergaard M, Rasmussen HH, Gromov P, Gromova I, Varmark H, Palsdottir H, Magnusson N, Andersen I, Basse B, Lauridsen JB, Ratz G, Wolf H, Orntoft TF, Celis P, Celis A: A comprehensive protein resource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis 1999;20:300-309.
67. Celis JE, Wolf H, Ostergaard M: Bladder squamous cell carcinoma biomarkers derived from proteomics. Electrophoresis 2000;21:2115-2121.
68. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Orntoft TF, Rasmussen HH: Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996;56:4782-4790.
69. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE: Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111-4117.
70. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, Rasmussen HH, Orntoft TF, Hein B, Wolf H, Celis A: Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: A novel strategy for identifying metaplastic lesions. Cancer Res 1999;59:3003-3009.
71. Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, Orntoft TF: Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol 1996;155:2105-2112.
72. Ostergaard M, Wolf H, Orntoft TF, Celis JE: Psoriasin (S100A7): A putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 1999;20: 349-354.
73. Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, Orntoft TF: Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol 1996;155:2105-2112.
74. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson RR: Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996;56:1690-1694.
75. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH: Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-2625.
76. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright JG Jr: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-1502.
77. Tsai YC, Harrison HH, Lee C, Daufeldt JA, Oliver L, Grayhack JT: Systematic characterization of human prostatic fluid proteins with two-dimensional electrophoresis. Clin Chem 1984;30: 2026-2030.
78. Grover PK, Resnick MI: Analysis of prostatic fluid: Evidence for the presence of a prospective marker for prostatic cancer. Prostate 1995;26:12-18.
79. Grover PK, Resnick MI: High-resolution two-dimensional electrophoretic analysis of urinary proteins of patients with prostatic cancer. Electrophoresis 1997;18:814-818.
80. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993;53:744-746.
81. Partin AW, Briggman JV, Subong EN, Szaro R, Oreper A, Wiesbrock S, Meyer J, Coffey DS, Epstein JI: Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 1997;50: 800-808.
82. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF III, Emmert-Buck MR: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000;21: 2235-2242.
83. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M: Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;l:377-396.
84. Bocker T, Bittinger A, Wieland W, Buettner R, Fauser G, Hofstaedter F, Ruschoff J: In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate. Mod Pathol 1995;226-231.
85. Alaiya AA, Franzen B, Auer G, Linder S: Cancer proteomics: From identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis 2000;21 : 1210-1217.
86. Alaiya AA, Oppermann M, Langridge J, Roblick U, Egevad L, Brindstedt S, Hellstrom M, Linder S, Bergman T, Jornvall H, Auer G: Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sei 2001;58:307-311.
87. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and cq-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
88. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279: 1542-1547.
89. Ornstein DK, Englert C, Gillespie JW, Paweletz CP, Linehan WM, Emmert-Buck MR, Petricoin EF III: Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin Cancer Res 2000;6:353-356.
90. Cole KA, Krizman DB, Emmert-Buck MR: The genetics of cancer - A 3D model. Nat Genet 1999;21:38-4l.
91. Chetcuti A, Margan SH, Russell P, Mann S, Millar DS, Clark SJ, Rogers J, Handelsman DJ, Dong Q: Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001; 61:6331-6334.
92. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF III: Loss of annexin l correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000;60:6293-6297.
93. Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD, Lau SS, Tang DG: Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003;22:1475-1485.
94. Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III, Emmert-Buck MR: Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33:9-15.
95. Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR, Cole KA, Wang QH, Huang J, Hu N, Yip TT, Rich WE, Kohn EC, Linehan WM, Weber T, Taylor P, Emmert-Buck MR, Liotta LA, Petricoin EF: Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 2000;49:34-42.
96. Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A: Proteinchip® surface-enhanced laser desorption/ionization mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999;2:264-276.
97. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GL Jr: Normal, benign, preneoplastic and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002;8:2541-2552.
98. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-1578.
99. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
100. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61: 6029-6033.
101. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF III, Liotta LA: Reverse-phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001 ; 20:1981-1989.
102. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB: Antibody micro-array profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers. Proteomics 2003;3:56-63.
103. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W: Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63.
104. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P: Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997;18:599-604.
105. Sarto C, Frutiger S, Cappellano F, Sanchez JC, Doro G, Catanzaro F, Hughes GJ, Hochstrasser DF, Mocarelli P: Modified expression of plasma glutathione peroxidase and manganese Superoxide dismutase in human renal cell carcinoma. Electrophoresis 1999;20:3458-3466.
106. Balabanov S, Zimmermann U, Protzel C, Scharf C, Klebingat KJ, Walther R: Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem 2001;268:5977-5980.
107. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE: Proteomic changes in renal cancer, and coordinate demonstration of both glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003;3:1620-1632.
108. Von Eggeling F, Junker K, Fiedle W, Wollscheid V, Durst M, Claussen U, Ernst G: Mass spectrometry meets chip technology: A new proteomic tool in cancer research? Electrophoresis 2001; 22:2898-2902.
109. Fetsch PA, Simone NL, Bryant-Greenwood PK, Marincola FM, Filie AC, Petricoin EF, Liotta LA, Abati A: Proteomic evaluation of archival cytologie material using SELDI affinity mass spectrometry: Potential for diagnostic applications. Am J Clin Pathol 2002; 118:870-876.
110. Lichtenfels R, Ackermann A, Kellner R, Seliger B: Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis 2001;22:1801-1809.
111. Prasannan L, Misek DE, Hinderer R, Michon J, Geiger JD, Hanash SM: Identification of β-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 2000;6:3949-3956.
112. Hanash S, Brichory F, Beer D: A proteomic approach to the identification of lung cancer markers. Dis Markers 2001;17:295-300.
113. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, Hanash SM: Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001;7:3328-3335.
114. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S: Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001;61:7908-7912.
115. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, Selby PJ, Banks RE: Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003;3:45-55.
116. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR: Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001;!: 890-898.
117. Lichtenfels R, Kellner R, Bukur J, Beck J, Brenner W, Ackermann A, Seliger B: Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002; 2:561-570.
118. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B: Identification of metabolic enzymes in renal cell carcinoma utilizing Proteomex analyses. Biochim Biophys Acta 2003;1646:21-31.
119. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL: Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 1998;8:657-665.
120. Santarosa M, Favaro D, Quaia M, Galligioni E: Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997;33: 873-877.